Phase 2 Ovarian Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Women aged 18 or older who have signed the written consent form
• Women with a general health status rated as fully active or restricted only in physically strenuous activity (this is measured using a standard scale called ECOG, scored 0 or 1)
• People with a life expectancy of at least 3 months
• People diagnosed with a specific type of ovarian cancer (epithelial, non-mucinous) — this includes ovarian, fallopian tube, or primary peritoneal cancer — where the cancer came back or grew more than 6 months after the last dose of platinum-based chemotherapy
• People who carry a BRCA gene mutation must have previously received a type of treatment called a PARP inhibitor before joining (confirm with trial site)
• People whose cancer can be measured on scans according to standard criteria used by the trial team
• People who are able to provide a stored tumour tissue sample (a preserved tissue block from a previous biopsy or surgery)
• People whose liver, kidneys, and other organs are functioning at an adequate level
• People of reproductive potential who agree to use effective contraception during the trial and for 6 months after the last dose of treatment

Who may not be able to join:

• People with certain other types of ovarian tumours, such as mucinous cancer or sex cord stromal cell tumours
• People who have cancer that has spread to the brain or the lining of the brain or spinal cord
• People with fluid build-up around the lungs, heart, or abdomen that cannot be controlled and needs repeated draining
• People who have had another active cancer within the past 3 years
• People who have received systemic cancer treatment within 2 weeks before joining the trial
• People who have previously received treatments that work by targeting the immune system's response to tumours
• People who have had major surgery, an open biopsy, or a significant injury within 4 weeks before joining, or who are expected to need major surgery during the trial
• People with an active or recurring autoimmune disease (a condition where the immune system attacks the body's own tissues)
• People who need regular high-dose steroid medication or other immune-suppressing drugs within 14 days before joining (confirm with trial site for specific dosage thresholds)
• People who have received a live vaccine within 4 weeks before joining
• People with a known condition that weakens the immune system, including those who test positive for HIV
• People with a history of receiving a donated organ or donated stem cell transplant
• People with a known history of interstitial lung disease or non-infectious lung inflammation
• People with a serious infection that required or requires hospitalisation
• People with an active infection currently requiring treatment
• People with active hepatitis B or active hepatitis C
• People with active inflammatory bowel disease or active diverticulitis (inflammation of pouches in the bowel)
• People with significant heart or blood vessel disease (confirm with trial site for specific conditions)
• People who still have unresolved side effects from previous cancer treatment
• People with a history of severe allergic reactions to monoclonal antibody treatments (a type of targeted therapy)
• Women who are pregnant or breastfeeding
• People with any other condition that the trial doctor believes may make it unsafe to receive the study drug
• People with a known allergy or medical reason to avoid paclitaxel or carboplatin (relevant to certain groups within the trial)
• People with a known allergy or medical reason to avoid Olaparib (relevant to certain groups within the trial)
• People with a known allergy or medical reason to avoid any component of the study drug AK112, or a medical condition that affects its safety

Important: Always verify eligibility with the trial site directly before applying.